摘要
BACKGROUND: Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor. However, if tissue is scant, another strategy is to use circulating tumour DNA (ctDNA), but this method needs validation in clinical trials. We did a prospective clinical trial to assess ctDNA-based EGFR mutation detection as a selection criterion for patients with lung adenocarcinoma receiving gefitinib as first-line treatment. METHODS: BENEFIT is a multicentre, single-arm, phase 2 clinical trial at 15 centres in China. Patients aged 18-75 years with stage IV metastatic lung adenocarcinoma and EGFR mutations detected in ctDNA were given oral gefitinib 250 mg once daily as first-line treatment. The primary endpoint was the proportion achieving an objective response. Secondary endpoints included median progression-free survival and safety. Next-generation sequencing (NGS) of a 168-gene panel was used for genetic analysis of baseline blood samples. The primary efficacy analysis was done by intention to treat in patients who had at least one post-baseline tumour assessment. The safety analysis was done in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02282267. FINDINGS: Between Dec 25, 2014, and Jan 16, 2016, 426 patients were screened for the trial, of whom 188 with EGFR mutations in ctDNA were enrolled and received gefitinib. 183 patients had one or more post-baseline tumour assessment and were included in the primary efficacy analysis. Median follow-up was 14·5 months (IQR 12·2-16·5). At the time of data cutoff (Jan 31, 2017), 152 patients had progressive disease or had died. The proportion achieving an objective response was 72·1% (95% CI 65·0-78·5). Median progression-free survival was 9·5 months (95% CI 9·07-11·04). Of 167 patients with available blood samples, 147 (88%) showed clearance of EGFR mutations in ctDNA at week 8, and median progression-free survival was longer for these patients than for the 20 patients whose EGFR mutations persisted at week 8 (11·0 months [95% CI 9·43-12·85] vs 2·1 months [1·81-3·65]; hazard ratio [HR] 0·14, 95% CI 0·08-0·23; p<0·0001). From baseline NGS data in 179 patients, we identified three subgroups of patients: those with EGFR mutations only (n=58), those with mutations in EGFR and tumour-suppressor genes (n=97), and those with mutations in EGFR and oncogenes (n=24). Corresponding median progression-free survival in these subgroups was 13·2 months (95% CI 11·5-15·0), 9·3 months (7·6-11·0), and 4·7 months (1·9-9·3), respectively (EGFR mutations only vs mutations in EGFR and tumour-suppressor genes, HR 1·78, 95% CI 1·23-2·58; p=0·002; EGFR mutations only vs mutations in EGFR and oncogenes, 2·66, 1·58-4·49; p=0·0003). The most common grade 3 or 4 adverse events were hepatic function abnormalities (n=24). Serious adverse events were reported in 17 (9%) patients. No unexpected safety events for gefitinib were recorded. INTERPRETATION: Detection of EGFR mutations in ctDNA is an effective method to identify patients who might benefit from first-line gefitinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to gefitinib. FUNDING: Guangdong Association of Clinical Trials, AstraZeneca, National Natural Sciences Foundation Key Programme, and National Key Research and Development Programme of China.
- EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6Wu Yi Long*; Sequist Lecia V; Hu Cheng Ping; Feng Jifeng; Lu Shun; Huang Yunchao; Li Wei; Hou Mei; Schuler Martin; Mok Tony; Yamamoto Nobuyuki; O'Byrne Kenneth; Hirsh Vera; Gibson Neil; Massey Dan; Kim Miyoung; Yang James Chih Hsin*British Journal of Cancer, 2017, 116(2): 175-185.
- Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatmentProvencio Mariano; Serna-Blasco Roberto; Franco Fabio; Calvo Virgina; Royuela Ana; Auglytė Milda; Sánchez-Hernández Alfredo; de Julián Campayo María; García-Girón Carlos; Dómine Manuel; Blasco Ana; Sánchez José M.; Oramas Juana; Bosch-Barrera Joaquim; Sala María Á.; Sereno María; Ortega Ana L.; Chara Luis; Hernández Berta; Padilla Airam; Coves Juan; Blanco Remedios; Balsalobre José; Mielgo Xabier; Bueno Coralia; Jantus-Lewintre Eloisa; Molina-Vila Miguel Á.; Romero AtochaEuropean Journal of Cancer, 2021, 149.
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung CancerZhou Qing; Zhang Xu Chao; Chen Zhi Hong; Yin Xiao Lu; Yang Jin Ji; Xu Chong Rui; Yan Hong Hong; Chen Hua Jun; Su Jian; Zhong Wen Zhao; Yang Xue Ning; An She Juan; Wang Bin Chao; Huang Yi Sheng; Wang Zhen; Wu Yi Long*Journal of Clinical Oncology, 2011, 29(24): 3316-3321.被引 80
